quinoxalines has been researched along with Cranial Nerve II Injuries in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bartlett, CA; Fitzgerald, M; Gavriel, N; Gopalasingam, G; Majimbi, M; McGonigle, T; Rodger, J; Toomey, LM | 1 |
| Bartlett, CA; Chiha, W; Fitzgerald, M; Giacci, MK; Harvey, AR; Hodgetts, SI; O'Hare Doig, RL; Smith, NM; Yates, NJ | 1 |
| Bartlett, CA; Fitzgerald, M; Gopalasingam, G; Majimbi, M; Rodger, J; Toomey, LM | 1 |
| Chindasub, P; Dai, Y; Duong-Polk, KX; Leung, CK; Lindsey, JD; Weinreb, RN | 1 |
| Fujita, Y; Sato, A; Yamashita, T | 1 |
| Brown, AM; Chen, S; Evans, RD; Hamner, MA; Ransom, BR; Yang, X; Ye, ZC | 1 |
| Chindasub, P; Duong-Polk, KX; Hammond, D; Leung, CK; Lindsey, JD; Weinreb, RN | 1 |
| Jang, I; Jeoung, JW; Kim, H; Kim, KE; Kim, YJ; Moon, H; Park, KH | 1 |
| Jonas, JB; Ma, K; Pu, M; Xu, L; Zhang, H; Zhang, S | 1 |
| Dermon, C; Panagis, L; Prokosch, V; Thanos, S; Volk, GF | 1 |
| Bancroft, WJ; Beazley, LD; Dunlop, SA; Rodger, J; Stirling, RV; Symonds, AC; Tee, LB | 1 |
| Beazley, LD; Dunlop, SA; Rodger, J; Stirling, RV; Taylor, AL | 1 |
| Schwartz, M; Wheeler, LA; Yoles, E | 1 |
| Groner, Y; Harris-Cerruti, C; Levkovitch-Verbin, H; Schwartz, M; Wheeler, LA; Yoles, E | 1 |
| Dreyer, EB; Naskar, R; Schuettauf, F; Vorwerk, CK; Zurakowski, D | 1 |
| Gil, DW; Wheeler, LA; WoldeMussie, E | 1 |
16 other study(ies) available for quinoxalines and Cranial Nerve II Injuries
| Article | Year |
|---|---|
Comparing modes of delivery of a combination of ion channel inhibitors for limiting secondary degeneration following partial optic nerve transection.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Drug Therapy, Combination; Female; Imidazoles; Myelin Sheath; Nerve Degeneration; Optic Nerve; Optic Nerve Injuries; Piperazines; Quinoxalines; Rats; Receptors, AMPA; Receptors, Purinergic P2X7; Rosaniline Dyes | 2019 |
Specific ion channels contribute to key elements of pathology during secondary degeneration following neurotrauma.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Disease Models, Animal; Female; Imidazoles; Macrophages; Microglia; Nerve Degeneration; Nystagmus, Optokinetic; Optic Nerve Injuries; Oxidative Stress; Piperazines; Purinergic P2X Receptor Antagonists; Quinoxalines; Random Allocation; Ranvier's Nodes; Rats; Receptors, AMPA; Receptors, Purinergic P2X7 | 2017 |
Comparison of ion channel inhibitor combinations for limiting secondary degeneration following partial optic nerve transection.
Topics: Animals; Calcium Channel Blockers; Calcium-Binding Proteins; Cell Adhesion Molecules, Neuronal; Disease Models, Animal; Drug Delivery Systems; Drug Therapy, Combination; Ectodysplasins; Female; Imidazoles; Ion Channels; Macrophages; Microfilament Proteins; Microglia; Nerve Degeneration; Nystagmus, Optokinetic; Oligodendrocyte Transcription Factor 2; Optic Nerve Injuries; Piperazines; Quinoxalines; Rats; Receptor, Platelet-Derived Growth Factor alpha; Rosaniline Dyes; Tubulin | 2019 |
Brimonidine protects against loss of Thy-1 promoter activation following optic nerve crush.
Topics: Adrenergic alpha-2 Receptor Agonists; Analysis of Variance; Animals; Brimonidine Tartrate; Cell Count; Disease Models, Animal; Female; Longitudinal Studies; Male; Mice; Microscopy, Fluorescence; Nerve Crush; Optic Nerve Injuries; Promoter Regions, Genetic; Protective Agents; Quinoxalines; Retinal Ganglion Cells; Thy-1 Antigens | 2013 |
Brimonidine promotes axon growth after optic nerve injury through Erk phosphorylation.
Topics: Animals; Axons; Brimonidine Tartrate; Gene Expression Regulation; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Optic Nerve; Optic Nerve Injuries; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinoxalines; Receptor, trkB; Receptors, Nerve Growth Factor; Regeneration | 2013 |
Novel hypoglycemic injury mechanism: N-methyl-D-aspartate receptor-mediated white matter damage.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Aspartic Acid; Brain; Calcium; Disease Models, Animal; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic Acid; Glycine; Glycogen; Hydrogen-Ion Concentration; Hypoglycemia; Kynurenic Acid; Lactic Acid; Leukoencephalopathies; Mice; Mice, Inbred C57BL; Optic Nerve Injuries; Quinoxalines; Receptors, N-Methyl-D-Aspartate | 2014 |
Differential protection of injured retinal ganglion cell dendrites by brimonidine.
Topics: Animals; Brimonidine Tartrate; Cytoprotection; Dendrites; Female; Male; Mice; Mice, Inbred Strains; Microscopy, Fluorescence; Nerve Crush; Optic Nerve Injuries; Quinoxalines; Retinal Ganglion Cells | 2015 |
Neuroprotective Effects of Human Serum Albumin Nanoparticles Loaded With Brimonidine on Retinal Ganglion Cells in Optic Nerve Crush Model.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Cell Survival; Disease Models, Animal; Drug Carriers; Humans; Immunohistochemistry; Intravitreal Injections; Male; Nanoparticles; Nerve Crush; Optic Nerve; Optic Nerve Injuries; Quinoxalines; Rats; Rats, Sprague-Dawley; Retinal Ganglion Cells; Serum Albumin | 2015 |
Effect of brimonidine on retinal ganglion cell survival in an optic nerve crush model.
Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Cell Count; Cell Survival; Disease Models, Animal; Injections, Intraperitoneal; Nerve Crush; Neuroprotective Agents; Optic Nerve Injuries; Quinoxalines; Rats; Rats, Sprague-Dawley; Retinal Ganglion Cells | 2009 |
Alpha2-adrenergic receptors and their core involvement in the process of axonal growth in retinal explants.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Autoradiography; Axons; Brimonidine Tartrate; Clonidine; Disease Models, Animal; Electrophoresis, Gel, Two-Dimensional; Fluorescent Antibody Technique, Indirect; Glaucoma; Glial Fibrillary Acidic Protein; Optic Nerve Injuries; Organ Culture Techniques; Platelet Activating Factor; Protein Disulfide-Isomerases; Proteomics; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Receptors, Laminin; Retina; Retinal Degeneration; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2010 |
Failure to form a stable topographic map during optic nerve regeneration: abnormal activity-dependent mechanisms.
Topics: Animals; Blotting, Western; Brain Mapping; Electrophysiology; Evoked Potentials, Visual; Excitatory Amino Acid Antagonists; Immunohistochemistry; Lizards; Nerve Crush; Nerve Regeneration; Optic Nerve; Optic Nerve Injuries; Quinoxalines; Receptors, AMPA; Receptors, Kainic Acid; Receptors, N-Methyl-D-Aspartate; Time Factors; Valine | 2003 |
The balance of NMDA- and AMPA/kainate receptor-mediated activity in normal adult goldfish and during optic nerve regeneration.
Topics: 2-Amino-5-phosphonovalerate; Action Potentials; Animals; Excitatory Amino Acid Antagonists; Goldfish; Nerve Regeneration; Optic Nerve Injuries; Quinoxalines; Receptors, AMPA; Receptors, Kainic Acid; Receptors, N-Methyl-D-Aspartate; Time Factors | 2005 |
Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration.
Topics: Action Potentials; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Axons; Brimonidine Tartrate; Cell Count; Cell Survival; Clonidine; Disease Models, Animal; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Male; Nerve Degeneration; Neuroprotective Agents; Optic Nerve; Optic Nerve Diseases; Optic Nerve Injuries; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Retinal Ganglion Cells; Timolol; Yohimbine | 1999 |
RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection.
Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Cell Death; Cell Survival; Mice; Mice, Transgenic; Nerve Crush; Neuroprotective Agents; Optic Nerve; Optic Nerve Injuries; Oxidative Stress; Quinoxalines; Receptors, Adrenergic, alpha-2; Retinal Ganglion Cells; Superoxide Dismutase | 2000 |
Ganglion cell loss after optic nerve crush mediated through AMPA-kainate and NMDA receptors.
Topics: Animals; Cell Survival; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Nerve Crush; Neuroprotective Agents; Optic Nerve Injuries; Quinoxalines; Rats; Rats, Long-Evans; Receptors, AMPA; Receptors, Kainic Acid; Receptors, N-Methyl-D-Aspartate; Retinal Ganglion Cells | 2000 |
Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma.
Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Cell Count; Cell Survival; Immunoenzyme Techniques; Intraocular Pressure; Neuroprotective Agents; Ocular Hypertension; Optic Nerve Injuries; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Retina; Retinal Ganglion Cells; Signal Transduction | 2001 |